Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bliss

Showing results (311-320 of 378) with videos related to

Pageof 38
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane studyJudith M Bliss, Lucy S Kilburn, Robert E Coleman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trialI E Smith, R P A'Hern, G A Coombes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 24, 2015
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†V Speirs, G Viale, K Mousa, et al.
NPJ Breast Cancer|June 19, 2020
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemicMitch Dowsett, Matthew J Ellis, J Michael Dixon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2005
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCGD Nitti, J Wils, J Guimaraes Dos Santos, et al.
Nature Communications|May 31, 2020
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerNeha Chopra, Holly Tovey, Alex Pearson, et al.
Pediatric Research|March 4, 2020
Challenges in developing a consensus definition of neonatal sepsisMatthew McGovern, Eric Giannoni, Helmut Kuester, et al.
Molecular Therapy. Methods & Clinical Development|August 29, 2024
A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for vaccine and gene therapy applicationsCarly M Bliss, Sarah L Hulin-Curtis, Marta Williams, et al.
The Lancet. Oncology|June 5, 2019
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trialIan Judson, James P Morden, Lucy Kilburn, et al.
Breast Cancer Research and Treatment|May 17, 2018
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancerErik J Blok, Charla C Engels, Geeske Dekker-Ensink, et al.
Pageof 38

Showing results (311-320 of 378) with videos related to

Sort By:
Pageof 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane studyJudith M Bliss, Lucy S Kilburn, Robert E Coleman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trialI E Smith, R P A'Hern, G A Coombes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 24, 2015
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†V Speirs, G Viale, K Mousa, et al.
NPJ Breast Cancer|June 19, 2020
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemicMitch Dowsett, Matthew J Ellis, J Michael Dixon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2005
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCGD Nitti, J Wils, J Guimaraes Dos Santos, et al.
Nature Communications|May 31, 2020
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerNeha Chopra, Holly Tovey, Alex Pearson, et al.
Pediatric Research|March 4, 2020
Challenges in developing a consensus definition of neonatal sepsisMatthew McGovern, Eric Giannoni, Helmut Kuester, et al.
Molecular Therapy. Methods & Clinical Development|August 29, 2024
A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for vaccine and gene therapy applicationsCarly M Bliss, Sarah L Hulin-Curtis, Marta Williams, et al.
The Lancet. Oncology|June 5, 2019
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trialIan Judson, James P Morden, Lucy Kilburn, et al.
Breast Cancer Research and Treatment|May 17, 2018
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancerErik J Blok, Charla C Engels, Geeske Dekker-Ensink, et al.
Pageof 38